Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
Acid, Add, advisory, afford, aim, AOC, AstraZeneca, attack, attainment, autoinflammatory, baseline, BCVA, begun, breast, bulk, center, chart, cisplatin, clearance, computerized, consortium, cryopyrin, CTEP, daily, defray, deposit, derecognition, disqualifying, Eli, embryonic, episode, fatigue, fluorouracil, fluouracil, FOLFIRI, Folinic, formalized, forward, France, goal, gout, graph, gynecological, Imclone, Insider, inspected, Institue, interfering, interval, irinotecan, kind, knockout, leucovorin, Ligand, Lilly, lt, median, Medicaid, Medicare, medium, metastatic, move, MWS, NIH, nonvested, North, NSCLA, occupy, OCT, ocular, optionee, oxaliplatin, oxygen, pancreatic, payer, pole, pose, posterior, predecessor, prostate, provoke, rash, ready, reclassified, recurrent, regimen, regression, reinvestment, resistant, respiratory, ribonucleic, rilonacept, sarcoma, satisfactory, Scan, score, showing, site, SMA, soft, stem, submission, suggesting, sustained, switch, switched, symptom, Taxotere, temperature, tenant, therefrom, top, tract, traditional, upper, urothelium, VelocImmune®and, VelocImmune®technology
Removed:
acquired, added, advice, affiliated, aged, April, attached, attempt, AXOKINE, brought, buy, care, close, collateral, commitment, complaint, conference, consistent, consolidated, designated, District, ending, entitle, equaled, examine, excluding, Eyetech, fifteen, fixed, forgiven, forma, fused, growing, immunoglobulin, implementation, Junior, lapsing, largely, misstated, negotiation, null, occurrence, owner, participating, partnership, permission, pledged, prepared, prescribed, redeemed, remain, retroactively, scheduled, Southern, Sumitomo, superseded, TDA, tender, thereunder, thousandth, tied, transaction, transfer, unit, violation, void, yielded
Filing tables
Filing exhibits
- 10-K Annual report
- 10.14 EX-10.14: Non Exclusive License and Material Transfer Agreement
- 12.1 EX-12.1: Statement Re: Computation of Ratio of Earnings to Combined Fixed Charges
- 23.1 EX-23.1: Consent of Pricewaterhousecoopers LLP
- 31.1 EX-31.1: Certification
- 31.2 EX-31.2: Certification
- 32 EX-32: Certification
Related press release
REGN similar filings
External links